Advertisement

PET/CT with Standard Non-FDG Tracers in Multiple Myeloma

  • Cristina NanniEmail author
Chapter
  • 196 Downloads

Abstract and Aims

Beside FDG, there is an emerging role of non-FDG tracers for the evaluation of Multiple Myeloma at onset. This because it was proved that there may be a quote of low metabolic myelomas that may present a low FDG uptake, possibly resulting in an underestimation of the number of focal lesions.

This chapter aims to:
  • Discuss the causes of false negativity at FDG

  • Discuss the contribution of 11C-Methionine in Multiple Myeloma

  • Discuss the contribution of 11C-18F-Choline in Multiple Myeloma

Keywords

Multiple myeloma Non-FDG tracers 11C-Choline 18F-Choline 11C-Methionine Functional imaging 

References

  1. 1.
    Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker BA, Epstein J, Zangari M, van Rhee F, Meissner T, Goldschmidt H, Hemminki K, Houlston R, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130(1):30–4.  https://doi.org/10.1182/blood-2017-03-774422. Epub 2017 Apr 21. PubMed PMID: 28432222; PubMed Central PMCID: PMC5501152.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kircher S, Stolzenburg A, Kortuem KM, Kircher M, Da Via M, Samnick S, Buck A, Einsele H, Rosenwald A, Lapa C. Hexokinase-2 expression in MET-positive FDG-negative multiple myeloma. J Nucl Med. 2018. pii: jnumed.118.217539.  https://doi.org/10.2967/jnumed.118.217539. [Epub ahead of print]. PubMed PMID: 30389821.CrossRefGoogle Scholar
  3. 3.
    Hammerton K, Cooper DA, Duckett M, Penny R. Biosynthesis of immunoglobulin in human immunoproliferative diseases. I. Kinetics of synthesis and secretion of immunoglobulin and protein by bone marrow cells in myeloma. J Immunol. 1978;121(2):409–17.PubMedGoogle Scholar
  4. 4.
    Dankerl A, Liebisch P, Glatting G, Friesen C, Blumstein NM, Kocot D, Wendl C, Bunjes D, Reske SN. Molecular imaging with 11C-methionine PET/CT—initial experience. Radiology. 2007;242(2):498–508.CrossRefGoogle Scholar
  5. 5.
    Lapa C, Knop S, Schreder M, Rudelius M, Knott M, Jörg G, Samnick S, Herrmann K, Buck AK, Einsele H, Lückerath K. 11C-Methionine-PET in multiple myeloma: correlation with clinical parameters and bone marrow involvement. Theranostics. 2016;6(2):254–61.CrossRefGoogle Scholar
  6. 6.
    Okasaki M, Kubota K, Minamimoto R, Miyata Y, Morooka M, Ito K, Ishiwata K, Toyohara J, Inoue T, Hirai R, Hagiwara S, Miwa A. Comparison of (11)C-4′-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma. Ann Nucl Med. 2015;29(3):224–32.CrossRefGoogle Scholar
  7. 7.
    Lapa C, Garcia-Velloso MJ, Lückerath K, Samnick S, Schreder M, Otero PR, Schmid JS, Herrmann K, Knop S, Buck AK, Einsele H, San-Miguel J, Kortüm KM. (11)C-Methionine-PET in multiple myeloma: a combined study from two different institutions. Theranostics. 2017;7(11):2956–64.  https://doi.org/10.7150/thno.20491. eCollection 2017. PubMed PMID: 28824728; PubMed Central PMCID: PMC5562228.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Mesguich C, Zanotti-Fregonara P, Hindié E. New perspectives offered by nuclear medicine for the imaging and therapy of multiple myeloma. Theranostics. 2016;6(2):287–90.CrossRefGoogle Scholar
  9. 9.
    Sanz G, Rioja J, Zudaire JJ, Beria'n JM, Richter JA. PET and prostate cancer. World J Urol. 2004;22:351–2.CrossRefGoogle Scholar
  10. 10.
    Ambrosini V, Farsad M, Nanni C, Rubello D, Fanti S. Image of the month: incidental finding of a 11C-choline PET positive solitary plasmacytoma lesion. Eur J Nucl Med Mol Imaging. 2006.Google Scholar
  11. 11.
    Nanni C, Zamagni E, Cavo M, Rubello D, Tacchetti P, Pettinato C, Farsad M, Castellucci P, Ambrosini V, Montini GC, Al-Nahhas A, Franchi R, Fanti S. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol. 2007;5:68. PubMed PMID: 17584499; PubMed Central PMCID: PMC1913918.CrossRefGoogle Scholar
  12. 12.
    Cassou-Mounat T, Balogova S, Nataf V, Calzada M, Huchet V, Kerrou K, Devaux JY, Mohty M, Talbot JN, Garderet L. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study. Eur J Nucl Med Mol Imaging. 2016;43(11):1995–2004.  https://doi.org/10.1007/s00259-016-3392-7. Epub 2016 Apr 28. PubMed PMID: 27121691.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Nuclear Medicine, AOU S.Orsola-MalpighiBolognaItaly

Personalised recommendations